OSI-420

 

Topic mentions per year

Topic mentions per year

2001-2017
02420012017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
BACKGROUND Although there have been several reports in which central nervous system (CNS) metastases of non-small cell lung… (More)
Is this relevant?
2010
2010
INTRODUCTION Although erlotinib, an orally active and selective tyrosine kinase inhibitor of epidermal growth factor receptor, is… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Patients with (a) recurrent malignant glioma (MG): glioblastoma (GBM) or recurrent anaplastic glioma (AG), and (b) nonprogressive… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2007
2007
PURPOSE To report cerebrospinal fluid (CSF) penetration of erlotinib and its metabolite OSI-420. EXPERIMENTAL DESIGN… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
Is this relevant?
2007
2007
An accurate and precise method was developed using HPLC-MS/MS to quantify erlotinib (OSI-774) and its O-desmethyl metabolite, OSI… (More)
Is this relevant?
2007
2007
Erlotinib hydrochloride is a small molecule inhibitor of epidermal growth factor receptor (EGFR). EGFR is over-expressed in… (More)
  • table 1
  • figure 1
  • table 2
Is this relevant?
Highly Cited
2006
Highly Cited
2006
PURPOSE To compare the pharmacokinetic variables of erlotinib in current smokers with nonsmokers after receiving a single oral… (More)
  • figure 2
  • table 2
  • figure 3
  • figure 4
Is this relevant?
2005
2005
A new method was developed and validated for quantitating OSI-774 and its metabolite OSI-420 in human plasma. Sample preparation… (More)
Is this relevant?
2003
2003
A new simple and specific method was developed and validated for the quantitative determination of OSI-774 (Tarceva, Erlotinib… (More)
Is this relevant?
Highly Cited
2001
Highly Cited
2001
PURPOSE To assess the feasibility of administering OSI-774, to recommend a dose on a protracted, continuous daily schedule, to… (More)
  • figure 1
  • table 2
  • table 3
  • table 4
  • figure 2
Is this relevant?